Skip to content
lifestyle.ukuncut.org.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Edgewise Therapeutics
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
September 2, 2026
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
August 24, 2026
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
August 6, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
June 3, 2026
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
June 1, 2026
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
March 10, 2026